AMG 397

Overview

AMG 397 is an oral small molecule inhibitor of MCL-1. It is being investigated as a treatment for multiple myeloma, acute myeloid leukemia, and non-hodgkins lymphoma.

SparkCures ID 330
Developed By Amgen
Generic Name AMG 397

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.